德国MET联盟登记的儿童和青少年后续甲状腺癌(1997-2023)
该回顾性队列研究分析了德国全国多中心恶性内分泌肿瘤研究(1997-2023)中登记的18岁以下儿童和青少年甲状腺癌,比较了后续甲状腺癌与原发性甲状腺癌的特征。505例甲状腺癌中66例(13.1%)为后续甲状腺癌,其5年总生存率为100.0%、甲状腺相关无事件生存率为82.5%。仅化疗后的后续甲状腺癌相比化疗联合放疗者潜伏期更短、肿瘤更大、诊断年龄更小,但总生存和无事件生存无差异。
要点
- 505例儿童青少年甲状腺癌中66例(13.1%)为后续甲状腺癌。
- 后续甲状腺癌相比原发性甲状腺癌体积更小但更常见多灶性。
- 仅化疗后的后续甲状腺癌相比化疗联合放疗者潜伏期更短、肿瘤更大、诊断年龄更小。
核心结论
- 后续甲状腺癌的表现特征与原发性甲状腺癌不同,但预后无显著差异。
- 仅化疗后的后续甲状腺癌相比化疗联合放疗者肿瘤更大、诊断年龄更小、潜伏期更短。
- 需要更多研究来识别可能促进化疗后甲状腺肿瘤发生的危险因素和机制。
研究设计与样本
- 回顾性队列研究,分析德国全国多中心恶性内分泌肿瘤研究(1997-2023)中登记的18岁以下儿童和青少年甲状腺癌。
- 比较第一原发性甲状腺癌与继发于儿童期癌症或造血干细胞移植(HSCT)后的后续甲状腺癌。
- 在后续甲状腺癌亚组中,比较仅化疗后发生的甲状腺癌与化疗联合放疗后发生的甲状腺癌。
主要发现
- 505例甲状腺癌患者中66例(13.1%)(38例男性,28例女性)为后续甲状腺癌。
- 后续甲状腺癌诊断的中位年龄为12.7岁(范围5.1-17.9),距首次恶性肿瘤或HSCT的中位潜伏期为7.3年(范围2.2-15.6)。
- 从后续甲状腺癌诊断起计算的5年总生存率(OS)和甲状腺相关无事件生存率(EFS)估计分别为100.0%和82.5%。
- 后续甲状腺癌相比第一原发性甲状腺癌体积更小但更常见多灶性。
- 仅化疗后的后续甲状腺癌相比化疗联合放疗者潜伏期更短(中位6.2 vs. 7.8年)、肿瘤更大(中位1.86 vs. 1.18 cm)、诊断年龄更小(中位11.5 vs. 13.7岁),总生存和无事件生存无差异。
关键数值与推荐
- 505例甲状腺癌患者中66例(13.1%)为后续甲状腺癌。
- 后续甲状腺癌诊断的中位年龄为12.7岁(范围5.1-17.9),中位潜伏期为7.3年(范围2.2-15.6)。
- 5年总生存率为100.0%,甲状腺相关无事件生存率为82.5%。
- 仅化疗后的后续甲状腺癌相比化疗联合放疗者:潜伏期中位6.2 vs. 7.8年,肿瘤大小中位1.86 vs. 1.18 cm,诊断年龄中位11.5 vs. 13.7岁。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更多研究来识别可能促进化疗后甲状腺肿瘤发生的危险因素和机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Introduction: Among childhood cancer survivors, the cumulative incidence rate of differentiated thyroid carcinomas (DTCs) is estimated to be 8-11%. Although the association of DTC with prior radiotherapy is well-studied, the association with chemotherapy remains less understood. Most studies focused on young adults, leaving a knowledge gap on subsequent DTC occurring in childhood and adolescence. Methods: In this retrospective cohort study, we analyzed DTCs in children and adolescents under 18 years of age who were registered with the national multicenter Malignant Endocrine Tumor studies in Germany (1997-2023). We compared patients with first primary DTC to those with subsequent DTC that developed after a history of childhood cancer or hematopoietic stem cell transplantation (HSCT). In the subsequent DTC subgroup, we compared DTCs following chemotherapy only to those following chemo- and radiotherapy. Results: Of 505 patients with DTCs, 66 (13.1%) (38 male, 28 female) were subsequent DTCs. The median age at subsequent DTC diagnosis was 12.7 years (range, 5.1-17.9), with a median latency of 7.3 years (range, 2.2-15.6) from the first malignancy or HSCT. The 5-year overall survival (OS) and thyroid-related adverse event-free survival (EFS) estimates from the diagnoses of a subsequent DTC were 100.0% and 82.5%, respectively. Prior treatment included chemotherapy in 64 patients, with 18 receiving chemotherapy alone. In all, 46 subsequent DTC patients had a history of external radiotherapy, including 2 treated with radiotherapy only and 14 with total body irradiation. Two patients received 131I-metaiodobenzylguanidine treatment. Subsequent DTCs versus first DTCs were smaller in size but more frequently multifocal. Subsequent DTCs following chemotherapy only, compared with chemo- and radiotherapy, developed after a shorter latency (median 6.2 vs. 7.8 years), and were larger (median 1.86 vs. 1.18 cm). Patients with subsequent DTCs following chemotherapy only were younger at diagnosis (median 11.5 vs. 13.7 years). No differences were observed for OS and EFS. Conclusions: Presenting features of subsequent DTCs differ from primary counterparts, although the prognosis is not significantly different. Subsequent DTCs following chemotherapy only versus chemo- and radiotherapy DTCs were larger and diagnosed in younger patients after a shorter latency. More research is needed to identify risk factors and mechanisms potentially contributing to thyroid tumorigenesis post-chemotherapy.
引用
- Kunstreich M, Ronckers CM, Lorenz K, et al. Subsequent Thyroid Carcinomas in Children and Adolescents Registered in the German MET Consortium (1997-2023). Thyroid. 2024. PMID: 39699646. doi:10.1089/thy.2024.0312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。